Breathe BioMedical has been selected to participate in the inaugural cohort of the University of Massachusetts Lowell’s M2D2 Impact Program. The Massachusetts Medical Device Development (M2D2) program, which takes place from October to December 2021, will provide Breathe BioMedical easy, affordable, and coordinated access to world-class researchers and resources.
The M2D2 Impact Program is a 12-week program that features business, clinical and regulatory resources to help overcome roadblocks to medical device commercialization. Breathe BioMedical will also have a market readiness assessment performed, in order to identify any potential barriers to commercialization. A mentor assigned to early-stage companies is responsible for opening doors to strategic relationships and partners to help achieve our commercial goals. At the end of the program, Breathe BioMedical will participate in a pitch competition to a broad investor network.
We are thrilled for the opportunities that the M2D2 project will provide for our team.
Breathe BioMedical welcomes the opportunity to grow our business network. If you are interested in partnering with Breathe BioMedical, email us at info@breathebiomedical.com.
-30-
About Breathe BioMedical: Breathe BioMedical is a Canadian medical device company developing and manufacturing ground-breaking technology for breath analytics including our FDA-listed breath collection device SohnoXB. Breath analytics involves the collection, processing and analysis of breath samples to identify biomarkers associated with specific diseases. Breathe BioMedical has completed a proof-of-concept study demonstrating their technology’s ability to detect lung cancer with accuracy of 86.1% close to, if not better than, levels for low-dose computed tomography (LDCT). While continuing research into lung cancer, Breathe BioMedical has partnered on two additional independent research studies to detect breast cancer and COVID-19with plans to expand research in 2022 to include neurodegenerative diseases. Breathe BioMedical’s research and development laboratory is in Moncton, New Brunswick. One day, detecting disease will be as easy as breathing in and out.
